A Baltimore, Maryland-based biotech company sold $175,000 in a debt offering, according to a Securities and Exchange Commission filing.
AsclepiX Therapeutics filed the Form D on Feb. 9, and said it would like to raise another $825,000.
Wendy Perrow is the CEO of AsclepiX Therapeutics. She is also responsible for managing the company’s business, clinical, financial, licensing and corporate development efforts.
AsclepiX Therapeutics aims to develop new peptide-based drugs to treat ocular diseases.
The form can be found here.
